News & Updates

Lower plasma angiotensin-converting enzyme 2 (ACE2) levels may partially mediate COVID-19 risks in individuals with overweight/obesity or low socioeconomic position (SEP; referring to low educational attainment), according to a large-scale Mendelian randomization study conducted by researchers at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK).

The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.

Treatment with metformin, along with lifestyle changes, initiated for the prevention of diabetes does not appear to reduce the risk of age-related macular degeneration, a study has found.

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Adding a once-weekly dose of semaglutide to lifestyle intervention successfully reduced body mass index (BMI) in adolescents with obesity, according to results of the phase IIIa STEP TEENS trial.

Neutrophil-to-lymphocyte ratio (NLR) is a significant predictor of new-onset ischaemic stroke in Chinese patients with type 2 diabetes mellitus (T2DM), the population-based Hong Kong Diabetes Study has shown.

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.